Hengsai Biotechnology

About Hengsai

About Kousai

Hengsai BiotechnologyFounded in 2018, is dedicated toDendritic Cell Vaccine (DC Vaccine)The company is a scientific and technological innovative enterprise and a national high-tech enterprise in R&D and industrialization. The company has successfully constructed the Eco-DCVax platform, aiming to break the technical barriers to industrialization and develop globalFirst-in-Classa high quality DC vaccine product that is safe, efficient and easy to administer. Developed products -therapeutic dendritic cell vaccineIt provides new ways and strategies for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases, and other diseases that are in urgent need of effective clinical treatments.

Premiere Pipeline: KSD-101

Indications: EBV-related hematologic and solid tumors